BRAF and metastatic malignant neoplasm in the lymph nodes: We calculated the adjusted hazard ratios (AHRs) (adjusted with age at diagnosis, sex, tumor size, extrathyroidal invasion, lymph node metastasis) for risk of recurrence in each category of DRS with and without BRAF mutation.